Form 8-K

8-K — Concentra Group Holdings Parent, Inc.

Accession: 0002014596-26-000042

Filed: 2026-05-07

Period: 2026-05-05

CIK: 0002014596

SIC: 8093 (SERVICES-SPECIALTY OUTPATIENT FACILITIES, NEC)

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — cghp-20260505.htm (Primary)

EX-99.1 (cghpearningsrelease-3312026.htm)

EX-99.2 (concentrainvestorpresent.htm)

GRAPHIC (concentrainvestorpresent001.jpg)

GRAPHIC (concentrainvestorpresent002.jpg)

GRAPHIC (concentrainvestorpresent003.jpg)

GRAPHIC (concentrainvestorpresent004.jpg)

GRAPHIC (concentrainvestorpresent005.jpg)

GRAPHIC (concentrainvestorpresent006.jpg)

GRAPHIC (concentrainvestorpresent007.jpg)

GRAPHIC (concentrainvestorpresent008.jpg)

GRAPHIC (concentrainvestorpresent009.jpg)

GRAPHIC (concentrainvestorpresent010.jpg)

GRAPHIC (concentrainvestorpresent011.jpg)

GRAPHIC (concentrainvestorpresent012.jpg)

GRAPHIC (concentrainvestorpresent013.jpg)

GRAPHIC (image.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: cghp-20260505.htm · Sequence: 1

cghp-20260505

FALSE000201459600020145962026-05-052026-05-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): May 5, 2026

_______________

CONCENTRA GROUP HOLDINGS PARENT, INC.

(Exact Name of Registrant as Specified in Its Charter)

_______________

001-42188

(Commission File Number)

Delaware

30-1006613

(State or Other Jurisdiction of Incorporation)

(I.R.S. Employer Identification No.)

5080 Spectrum Drive, Suite 1200W

Addison, TX, 75001

(Address of principal executive offices) (Zip code)

(972) 364-8000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.01 par value per share

CON

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 7, 2026, Concentra Group Holdings Parent, Inc. (the “Company”) issued a press release announcing its financial results for its first quarter ended March 31, 2026. A copy of the press release and financial schedules are attached as Exhibit 99.1 to this report and incorporated herein by reference.

The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.

Item 7.01 Regulation FD Disclosure.

Attached as Exhibit 99.2 and furnished for purposes of Regulation FD is a presentation published by the Company on May 7, 2026, in connection with its press release announcing its financial results for its first quarter ended March 31, 2026.

The information in this Current Report on Form 8-K (including Exhibit 99.2) is being furnished solely to satisfy the requirements of Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act.

Item 8.01 Other Events.

Dividend Declaration

On May 5, 2026, the Board of Directors declared a cash dividend of $0.0625 per share. The dividend will be payable on or about June 9, 2026, to stockholders of record as of the close of business on May 19, 2026.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

99.1

Press Release, dated May 7, 2026, announcing financial results for the first quarter ended March 31, 2026 and cash dividend.

99.2

Concentra Group Holdings Parent Inc. Presentation.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CONCENTRA GROUP HOLDINGS PARENT, INC.

Date: May 7, 2026

By:

/s/ Timothy Ryan

Timothy Ryan

Executive Vice President and Chief Legal Counsel

EX-99.1

Filename: cghpearningsrelease-3312026.htm · Sequence: 2

Document

NEWS RELEASE

FOR IMMEDIATE RELEASE

Concentra Group Holdings Parent, Inc. Announces Results

For Its First Quarter Ended March 31, 2026, Cash Dividend, and Raised FY 2026 Guidance

ADDISON, TEXAS — May 7, 2026 — Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services by number of locations, today announced results for its first quarter ended March 31, 2026, the declaration of a cash dividend, and raised guidance for full year 2026.

“Our strong start to 2026 is a testament to the trust our clients place in us to care for their most valuable asset: their people,” said Keith Newton, Chief Executive Officer of Concentra. “The meaningful growth in visit volumes we saw this quarter demonstrates that our clinical model and value proposition continue to lead in workers' compensation. Building on our exceptional operational and financial performance, we remain focused on achieving key strategic objectives and positioning Concentra to deliver long-term shareholder value.”

Matt DiCanio, Concentra’s President and Chief Financial Officer, added, “Our Q1 results demonstrate the inherent strength of our operating model, with broad-based growth across our business supporting our decision to raise our full-year guidance. Beyond the balance sheet, we are focused on disciplined execution of our de novo pipeline and are on track to complete our transition from Select Medical Corporation in the coming months. As an independent company, we are optimizing our operational platform and infrastructure to drive sustained excellence and capitalize on our unique position as a leading health partner for the American workforce.”

First Quarter 2026 Highlights

For the first quarter ended March 31, 2026:

•Revenue of $569.6 million, an increase of 13.7% from $500.8 million in Q1 2025

•Net income of $52.3 million, an increase of 28.7% from $40.6 million in Q1 2025

•Net income attributable to the Company of $50.5 million, and Adjusted Net Income Attributable to the Company of $51.5 million, an increase of 29.8% and 22.0% over prior year, respectively

•Earnings per share of $0.39 and Adjusted Earnings per Share of $0.40, an increase of $0.09 and $0.07 over prior year, respectively

•Adjusted EBITDA of $120.7 million, an increase of 17.6% from $102.7 million in Q1 2025

•Patient visits of 3,419,091, or 54,271 visits per day, an increase of 6.7% from 50,863 visits per day in Q1 2025

•Revenue per visit of $151.47, an increase of 3.1% from $146.94 in Q1 2025

•Net cash provided by operating activities of $21.0 million and Free Cash Flow of $9.9 million

•Capital expenditures of $11.1 million, a decrease of 29.5% from $15.7 million in Q1 2025

•Repurchases of approximately 0.7 million shares of common stock totaling $15.0 million

•Cash balance of $61.7 million and a net leverage ratio of approximately 3.4x

•Total occupational health centers of 632, compared to 627 at the end of Q1 2025

•Opened one de novo occupational health center and acquired three occupational health centers

•Total onsite health clinics of 411, compared to 160 at the end of Q1 2025

The definition of Adjusted EBITDA and a reconciliation of net income to Adjusted EBITDA are presented in table VII of this release. The definition of Adjusted Earnings per Share and a reconciliation of net income attributable to the Company and earnings per share on a fully diluted basis to Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share on a fully diluted basis are presented in table VIII of this release. The definition of Free Cash Flow and a reconciliation of net cash provided by operating activities to Free Cash Flow are presented in table IX of this release.

Balance Sheet

As of March 31, 2026, our balance sheet reflected cash of $61.7 million, total debt of $1,576.1 million and total assets of $2,889.8 million. Concentra’s net leverage ratio as of March 31, 2026 was 3.4x, which was in compliance with the financial covenant under our credit agreement.

Cash Flow

Cash flows provided by operating activities in the first quarter ended March 31, 2026 totaled $21.0 million compared to $11.7 million for the same quarter of the prior year. The increase in year over year cash flow from operations resulted from higher earnings in 2026. During the first quarter ended March 31, 2026, cash flow from investing activities resulted in cash used of $14.8 million, including capital expenditures of $11.1 million. Concentra had positive Free Cash Flow of $9.9 million in the first quarter ended March 31, 2026, compared to negative Free Cash Flow of $4.0 million for the same quarter of the prior year. Cash flow from financing activities used $24.4 million for the quarter, driven primarily by $15.0 million in repurchases of shares of common stock and $8.0 million in dividend payments. This resulted in a net decrease in cash of $18.2 million for the quarter.

Dividend

There is no assurance that future dividends will be declared. The declaration and payment of dividends in the future are at the discretion of the Board of Directors after taking various factors into account, including, but not limited to, the Company’s financial condition, operating results, available cash and current and anticipated cash needs, the terms of indebtedness, and other factors the Board of Directors may deem to be relevant.

2026 Business Outlook

Concentra raised its financial guidance for 2026. We now expect to deliver the following results:

•Revenue in the range of $2.275 billion to $2.375 billion

•Adjusted EBITDA in the range of $460 million to $480 million

•Net leverage ratio below 3.0x

•Free Cash Flow in the range of $215 million to $235 million

•Capital expenditures in the range of $70 million to $80 million

A reconciliation of full year 2026 Adjusted EBITDA expectations to net income is presented in table X of this release. A reconciliation of full year 2026 Free Cash Flow expectations to net cash provided by operating activities is presented in table XI of this release.

Company Overview

Concentra is the largest provider of occupational health services in the United States by number of locations, with the mission of improving the health of America’s workforce, one patient at a time. Our approximately 13,000 colleagues and affiliated physicians and clinicians support the delivery of an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. We support the care of approximately 54,000 patients each business day on average across 47 states and the District of Columbia at our 632 occupational health centers, 411 onsite health clinics at employer worksites, and Concentra Telemed as of March 31, 2026.

Conference Call

Concentra will host a conference call regarding its first quarter financial results and business outlook on Friday May 8, 2026, at 9 a.m. Eastern Time. The conference call will be a live webcast and can be accessed via this Earnings Call Webcast Link or via Concentra’s website at https://ir.concentra.com. A replay of the webcast will be available shortly after the call at the same locations.

Participants may join the audio-only version of the webcast or participate in the question-and-answer session by calling:

Toll Free: 888-506-0062

International: 973-528-0011

Participant Access: All dial-in participants should ask to join the Concentra call.

* * * * *

Certain statements contained herein that are not descriptions of historical facts are “forward-looking” statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), including statements related to Concentra’s 2026 and long-term business outlook. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements due to factors including the following:

•The frequency of work-related injuries and illnesses;

•Adverse changes to our relationships with employer customers, third-party payors, workers’ compensation provider networks or employer services networks;

•Changes to regulations, new interpretations of existing regulations, or violations of regulations;

•State fee schedule changes undertaken by state workers’ compensation boards or commissions and other third-party payors;

•Our ability to realize reimbursement increases at rates sufficient to keep pace with the inflation of our costs;

•Labor shortages, increased employee turnover or costs, and union activity could significantly increase our operating costs;

•Our ability to compete effectively with other occupational health centers, onsite health clinics at employer worksites, and healthcare providers;

•The impacts of any security breaches, cyberattacks, loss of data, or cybersecurity threats or incidents involving our, or our third-party vendors’, information technology systems, and any failure to comply with legal requirements related to data privacy, interoperability or data protection, including those governing the privacy and security of health information or other regulated, sensitive or confidential information;

•Negative publicity which can result in increased governmental and regulatory scrutiny and possibly adverse regulatory changes;

•Significant legal actions could subject us to substantial uninsured liabilities;

•Litigation and other legal and regulatory proceedings in the course of our business that could adversely affect our business and financial statements;

•Insurance coverage may not be sufficient to cover losses we may incur;

•Acquisitions may use significant resources, may be unsuccessful, and could expose us to unforeseen liabilities;

•Our exposure to additional risk due to our reliance on third parties in many aspects of our business;

•Our ability to manage relationships with managed affiliated professional medical groups (“Managed PCs”);

•Our facilities are subject to extensive federal and state laws and regulations relating to the privacy of individually identifiable information;

•Compliance with applicable data interoperability and information blocking rules;

•Facility licensure requirements in some states are costly and time-consuming, limiting or delaying our operations;

•Our ability to adequately protect and enforce our intellectual property and other proprietary rights;

•Adverse economic conditions in the U.S. or globally;

•Any negative impact on the global economy and capital markets resulting from geopolitical tensions;

•The impact of impairment of our goodwill and other intangible assets;

•Our ability to maintain satisfactory credit ratings;

•The effects of the Separation on our business;

•The negative impact of public threats such as a global pandemic or widespread outbreak of an infectious disease;

•The loss of key members of our management team;

•Our ability to attract and retain talented, highly skilled employees and a diverse workforce, and the succession of our senior management;

•Climate change, or legal, regulatory or market measures to address climate change;

•Increasing scrutiny and rapidly evolving expectations from stakeholders regarding ESG matters; and

•Changes in tax laws or exposures to additional tax liabilities.

Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the Securities and Exchange Commission, we are under no obligation to publicly update or revise any forward-looking statements, whether as a result of any new information, future events, or otherwise. You should not place undue reliance on our forward-looking statements. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results or performance.

Investor inquiries:

Bill Chapman

Vice President, Strategy & Investor Relations

972-725-6488

ir@concentra.com

SOURCE: Concentra Group Holdings Parent, Inc.

I. Condensed Consolidated Statements of Operations

For the Three Months Ended March 31, 2026 and 2025

(In thousands, except per share amounts, unaudited)

Three Months Ended March 31,

2026 2025

% Change

Revenue $ 569,555 $ 500,752 13.7 %

Costs and expenses:

Cost of services, exclusive of depreciation and amortization 399,086 357,101 11.8

General and administrative, exclusive of depreciation and amortization(1)

55,280 46,713 18.3

Depreciation and amortization 19,648 16,619 18.2

Total costs and expenses 474,014 420,433 12.7

Other operating income 69 — N/M

Income from operations 95,610 80,319 19.0

Other income and expense:

Loss on early retirement of debt — (875) N/M

Interest expense

(26,003) (25,548) 1.8

Income before income taxes 69,607 53,896 29.2

Income tax expense 17,315 13,254 30.6

Net income 52,292 40,642 28.7

Less: net income attributable to non-controlling interests 1,804 1,731 4.2

Net income attributable to the Company $ 50,488 $ 38,911 29.8 %

Basic and diluted earnings per common share:(2)

$ 0.39 $ 0.30

_________________________________________

(1) Includes transition services agreement fees of $1.6 million and $3.7 million for the three months ended March 31, 2026 and 2025, respectively.

(2) Refer to table II for calculation of earnings per common share.

N/M Not meaningful

II. Earnings per Share

For the Three Months Ended March 31, 2026 and 2025

(In thousands, except per share amounts, unaudited)

As of March 31, 2026 and 2025, the Company’s capital structure consists of common stock and unvested restricted stock. To calculate earnings per share (“EPS”) for the three months ended March 31, 2026 and 2025, the Company applied the two-class method because its unvested restricted shares were participating securities.

The following table sets forth the net income attributable to the Company, its shares, and its participating shares:

Three Months Ended March 31,

2026 2025

Net income $ 52,292 $ 40,642

Less: net income attributable to non-controlling interests 1,804 1,731

Net income attributable to the Company 50,488 38,911

Less: distributed and undistributed net income attributable to participating securities

1,065 455

Distributed and undistributed net income attributable to common shares

$ 49,423 $ 38,456

The following table sets forth the computation of EPS under the two-class method:

Three Months Ended March 31, 2026 Three Months Ended March 31, 2025

Net Income Allocation

Shares(1)

Basic and Diluted EPS

Net Income Allocation

Shares(1)

Basic and Diluted EPS

Common shares $ 49,423 125,781 $ 0.39 $ 38,456 126,647 $ 0.30

Participating securities 1,065 2,710 $ 0.39 455 1,500 $ 0.30

Total Company $ 50,488 128,491 $ 0.39 $ 38,911 128,147 $ 0.30

_________________________________________

(1) Represents the weighted average shares outstanding during the period.

III. Condensed Consolidated Balance Sheets

(In thousands, except par value and share data, unaudited)

March 31, 2026 December 31, 2025

ASSETS

Current assets:

Cash $ 61,699 $ 79,899

Accounts receivable 296,508 257,900

Prepaid income taxes 1,247 2,385

Other current assets 44,760 42,914

Total current assets 404,214 383,098

Operating lease right-of-use assets 500,645 483,652

Property and equipment, net 223,895 225,309

Goodwill 1,480,116 1,479,192

Other identifiable intangible assets, net 238,951 242,556

Non-current deferred tax asset 21,508 24,120

Other assets 20,431 20,461

Total assets $ 2,889,760 $ 2,858,388

LIABILITIES AND EQUITY

Current liabilities:

Current operating lease liabilities $ 85,252 $ 84,582

Current portion of long-term debt and notes payable 13,664 10,738

Accounts payable 31,737 21,005

Accrued and other liabilities 190,222 220,922

Total current liabilities 320,875 337,247

Non-current operating lease liabilities 461,232 443,642

Long-term debt, net of current portion 1,562,483 1,563,658

Non-current deferred tax liability 47,742 48,906

Other non-current liabilities 43,458 44,506

Total liabilities 2,435,790 2,437,959

Redeemable non-controlling interests 21,762 19,404

Stockholders’ equity:

Common stock, $0.01 par value, 700,000,000 shares authorized, 127,961,780 and 128,633,374 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively

1,280 1,286

Capital in excess of par 237,896 248,899

Retained earnings 186,845 146,448

Accumulated other comprehensive loss

(1,308) (3,352)

Total stockholders’ equity 424,713 393,281

Non-controlling interests 7,495 7,744

Total equity 432,208 401,025

Total liabilities and equity $ 2,889,760 $ 2,858,388

IV. Condensed Consolidated Statements of Cash Flows

For the Three Months Ended March 31, 2026 and 2025

(In thousands, unaudited)

Three Months Ended March 31,

2026 2025

Operating activities

Net income $ 52,292 $ 40,642

Adjustments to reconcile net income to net cash provided by operating activities:

Depreciation and amortization 19,648 16,619

Loss on early retirement of debt

— 51

Stock compensation expense 4,135 2,269

Amortization of debt discount and issuance costs 1,028 976

Deferred income taxes 815 (1,028)

Other 16 10

Changes in operating assets and liabilities, net of effects of business combinations:

Accounts receivable (38,626) (21,145)

Other current assets (1,785) (2,753)

Other assets 1,405 902

Accounts payable and accrued liabilities (17,909) (24,844)

Net cash provided by operating activities 21,019 11,699

Investing activities

Business combinations, net of cash acquired (3,760) (279,018)

Purchases of property and equipment (11,088) (15,732)

Proceeds from sale of assets 2 1

Net cash used in investing activities (14,846) (294,749)

Financing activities

Borrowings on revolving facilities — 50,000

Proceeds from term loans, net of issuance costs — 948,848

Payments on term loans (2,375) (847,875)

Borrowings of other debt 4,912 6,468

Principal payments on other debt (2,128) (4,695)

Dividends paid to common stockholders (8,017) —

Repurchase of common shares (14,996) —

Distributions to non-controlling interests

(1,769) (842)

Net cash (used in) provided by financing activities

(24,373) 151,904

Net decrease in cash

(18,200) (131,146)

Cash at beginning of period 79,899 183,255

Cash at end of period $ 61,699 $ 52,109

Supplemental information

Cash paid for interest $ 36,670 $ 38,137

Cash refund received for taxes

$ (781) $ (48)

V. Disaggregated Revenue

For the Three Months Ended March 31, 2026 and 2025

(In thousands, unaudited)

The following table disaggregates the Company’s revenue:

Three Months Ended March 31,

2026 2025

Occupational health centers:

Workers’ compensation $ 337,679 $ 302,107

Employer services 172,368 160,140

Consumer health 7,830 8,611

Other occupational health center revenue 2,024 2,064

Total occupational health center revenue 519,901 472,922

Onsite health clinics 37,196 16,550

Other 12,458 11,280

Total revenue $ 569,555 $ 500,752

VI. Key Statistics

For the Three Months Ended March 31, 2026 and 2025

The following table sets forth facility counts for our occupational health centers and onsite health clinics operating segments for the periods presented:

Three Months Ended March 31,

2026 2025

Facility Counts

Number of occupational health centers—start of period 628 552

Number of occupational health centers acquired 3 72

Number of occupational health centers de novos 1 3

Number of occupational health centers closed — —

Number of occupational health centers—end of period 632 627

Number of onsite health clinics—end of period 411 160

The following table sets forth operating statistics for our occupational health centers operating segment for the periods presented:

Three Months Ended March 31,

2026 2025 % Change

Number of patient visits

Workers’ compensation 1,583,343 1,444,880 9.6 %

Employer services 1,778,584 1,696,412 4.8 %

Consumer health 57,164 63,076 (9.4) %

Total 3,419,091 3,204,368 6.7 %

Visits per day volume

Workers’ compensation 25,132 22,935 9.6 %

Employer services 28,231 26,927 4.8 %

Consumer health 907 1,001 (9.4) %

Total 54,271 (3) 50,863 6.7 %

Revenue per visit(1)

Workers’ compensation $ 213.27 $ 209.09 2.0 %

Employer services 96.91 94.40 2.7 %

Consumer health 136.97 136.52 0.3 %

Total $ 151.47 $ 146.94 3.1 %

Business Days(2)

63 63

_________________________________________

(1) Represents the average amount of revenue recognized for each patient visit. Revenue per visit is calculated as total patient revenue divided by total patient visits. Revenue per visit as reported includes only the revenue and patient visits in our occupational health centers operating segment and does not include our onsite health clinics or other businesses operating segments.

(2) Represents the number of days in which normal business operations were conducted during the periods presented.

(3) Does not foot due to rounding.

VII. Net Income to Adjusted EBITDA Reconciliation

For the Three Months Ended March 31, 2026 and 2025

(In thousands, unaudited)

Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures that we believe provide useful insight into the underlying performance of our business by excluding items that may obscure trends in our core operating results. These metrics are not intended to be substitutes for U.S. GAAP measures such as net income and net income margin, and may differ from similarly titled metrics supported by other companies. We use these non-GAAP measures internally for budgeting, forecasting, and evaluating performance. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.

Adjusted EBITDA is a supplemental measure that we believe offers useful insight into the Company’s business performance by excluding items that do not reflect the core operations of the Company. We define Adjusted EBITDA as net income before interest, income taxes, depreciation and amortization, stock compensation expense, acquisition related costs, gains or losses on early retirement of debt, and separation transaction costs. We define Adjusted EBITDA margin as Adjusted EBITDA divided by total revenue. Adjusted EBITDA margin is a supplemental measure that we believe helps assess the efficiency of our operations on a normalized basis.

The following table reconciles net income to Adjusted EBITDA and net income margin to Adjusted EBITDA margin and should be referenced when we discuss Adjusted EBITDA and Adjusted EBITDA margin.

Three Months Ended March 31,

2026 2025

Amount

% of Revenue(4)

Amount

% of Revenue(4)

Reconciliation of Adjusted EBITDA:

Net income(1)

$ 52,292 9.2 % $ 40,642 8.1 %

Add (Subtract):

Income tax expense 17,315 3.0 13,254 2.6

Interest expense 26,003 4.6 25,548 5.1

Loss on early retirement of debt — — 875 0.2

Stock compensation expense 4,135 0.7 2,269 0.5

Depreciation and amortization 19,648 3.4 16,619 3.3

Separation transaction costs(2)

1,076 0.2 315 0.1

Nova and Pivot Onsite Innovations acquisition costs 219 0.0 3,137 0.6

Adjusted EBITDA(3)

$ 120,688 21.2 % $ 102,659 20.5 %

_________________________________________

(1) The percentage of revenue values on this row represent the net income margin for the period.

(2) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, system implementation, and software disposal costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the condensed consolidated statements of operations.

(3) The percentage of revenue values on this row represent the Adjusted EBITDA margin for the period.

(4) Totals in this column may not foot due to rounding.

VIII. Earnings per Share to Adjusted Earnings per Share Reconciliation

For the Three Months Ended March 31, 2026 and 2025

(In thousands, except per share amounts, unaudited)

Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are used by management to provide useful insight into the underlying performance of our business. Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are not measures of financial performance under U.S. GAAP and are not intended to be substitutes for U.S. GAAP measures such as net income attributable to the Company or earnings per share. These metrics may differ from similarly titled metrics supported by other companies. We believe that the presentation of Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share are important to investors because they are reflective of the financial performance of Concentra’s ongoing operations and provide better comparability of its results of operations between periods. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reported in our financial statements.

We define Adjusted Net Income Attributable to the Company as net income attributable to the Company, excluding gain (loss) on early retirement of debt, separation transaction costs, and acquisition costs, all on an after tax basis. We define Adjusted Earnings per Share as the Adjusted Net Income Attributable to the Company divided by the diluted weighted average shares outstanding.

The following table reconciles net income attributable to the Company and earnings per share on a fully diluted basis to Adjusted Net Income Attributable to the Company and Adjusted Earnings per Share on a fully diluted basis.

Three Months Ended March 31,

2026

Per Share(4)

2025

Per Share(4)

Reconciliation of Adjusted Net Income Attributable to the Company:(1)

Net income attributable to the Company

$ 50,488 $ 0.39 $ 38,911 $ 0.30

Adjustments:

Loss on early retirement of debt — — 875 0.01

Separation transaction costs(2)

1,076 0.01 315 0.00

Nova and Pivot Onsite Innovations acquisition costs

219 0.00 3,137 0.02

Total additions (subtractions), net

$ 1,295 $ 0.01 $ 4,327 $ 0.03

Less: tax effect of adjustments(3)

(322) (0.00) (1,064) (0.01)

Adjusted Net Income Attributable to the Company

$ 51,461 $ 0.40 $ 42,174 $ 0.33

Weighted average shares outstanding - diluted

128,491 128,147

_________________________________________

(1) Beginning in the second quarter of 2025, we updated the schedule for all periods presented to include Net Income Attributable to the Company. Management believes this measure will provide an improved insight into the performance of our business. As a result, the reconciliation for the three months ended March 31, 2025, has been recast to conform to the current period’s presentation.

(3) Tax impact is calculated using the annual effective tax rate, including discrete costs and benefits.

(4) Totals in this column may not foot due to rounding.

IX. Net Cash Provided by Operating Activities to Free Cash Flow Reconciliation

For the Three Months ended March 31, 2026 and 2025

(In thousands, unaudited)

Free Cash Flow is used by management to provide useful insight into the underlying performance of our business. Free Cash Flow is not a measure of financial performance under U.S. GAAP and is not intended to be a substitute for U.S. GAAP measures, such as net cash provided by operating activities. This metric may differ from similarly titled metrics supported by other companies. We believe that the presentation of Free Cash Flow is important to investors because it is reflective of the financial performance and cash flows of Concentra’s ongoing operations and provides a better comparability of its cash flows between periods. Investors should consider these measures in addition to, and not as a replacement for, U.S. GAAP results reporting in our financial statements.

We define Free Cash Flow as net cash provided by operating activities less net cash used in investing activities, excluding business combinations, net of cash acquired.

The following table reconciles net cash provided by operating activities to Free Cash Flow.

Three Months Ended March 31,

2026 2025

Reconciliation of Free Cash Flow:

Net cash provided by operating activities $ 21,019 $ 11,699

Add (Subtract):

Net cash used in investing activities (14,846) (294,749)

Business combinations, net of cash acquired 3,760 279,018

Free Cash Flow $ 9,933 $ (4,032)

X. 2026 Net Income to Adjusted EBITDA Reconciliation

Business Outlook for the Year Ending December 31, 2026

(In millions, unaudited)

The following is a reconciliation of full year 2026 Adjusted EBITDA expectations as computed at the low and high points of the range to the closest comparable U.S. GAAP financial measure. Refer to table VII for discussion of Concentra’s use of Adjusted EBITDA in evaluating financial performance and for the definition of Adjusted EBITDA. Each item presented in the below table is an estimation of full year 2026 expectations.

Range

Low

High

Net income attributable to the Company

$ 184 $ 199

Net income attributable to non-controlling interests 7 7

Net income $ 191 $ 206

Income tax expense 63 68

Interest expense 104 104

Income from operations 358 378

Stock compensation expense 21 21

Depreciation and amortization 80 80

Separation transaction costs 1 1

Adjusted EBITDA $ 460 $ 480

XI. 2026 Net Cash Provided by Operating Activities to Free Cash Flow Reconciliation

Business Outlook for the Year Ending December 31, 2026

(In millions, unaudited)

The following is a reconciliation of full year 2026 Free Cash Flow expectations as computed at the low and high points of the range to the closest comparable U.S. GAAP financial measure. Refer to table IX for discussion of Concentra’s use of Free Cash Flow in evaluating financial performance and for the definition of Free Cash Flow. Each item presented in the below table is an estimation of full year 2026 expectations.

Range

Low

High

Reconciliation of Free Cash Flow:

Net cash provided by operating activities $ 295 $ 305

Add (Subtract):

Net cash used in investing activities (84) (74)

Business combinations, net of cash acquired 4 4

Free Cash Flow $ 215 $ 235

EX-99.2

Filename: concentrainvestorpresent.htm · Sequence: 3

concentrainvestorpresent

©2026 Concentra Inc. All rights reserved. Forward-Looking Statements This presentation contains forward-looking statements that express Concentra Group Holdings Parent, Inc.'s ("Concentra," the "Company," "we" or "our") current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results that include, but are not limited to, financial guidance and other projections and forecasts. Forward looking statements include statements that are not historical facts and can be identified by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would” or similar expressions and the negatives of those terms. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the Company’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to, those factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those under “Risk Factors” therein. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond the Company’s control. Any forward looking statements made by the Company in this presentation speak only as of the date of this presentation and are expressly qualified in their entirety by the cautionary statements included in this presentation. Factors or events that could cause the Company’s actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company may not actually achieve the plans, intentions or expectations disclosed in its forward looking statements and you should not place undue reliance on its forward looking statements. The Company’s forward looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments or other strategic transactions it may make. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Use of Non-GAAP Financial Information In order to provide investors with greater insight, promote transparency and allow for a more comprehensive understanding of the information used by management in its financial and operational decision making, the Company supplements its condensed consolidated financial statements presented on a GAAP basis herein with certain non-GAAP financial information, including reconciliations of these non-GAAP measures to their most directly comparable available GAAP measures, which are included in this presentation, as well as in the Company’s quarterly financial press releases and related Form 8-K filings with the SEC. This information can be accessed for free by visiting www.concentra.com or www.sec.gov. We believe that the presentation of Adjusted EBITDA, Adjusted EBITDA margin, Return on Invested Capital, Free Cash Flow and FCF Conversion, as defined herein (collectively, the “Non-GAAP Measures”), are important to investors because they are commonly used as an analytical indicator of performance by investors within the healthcare industry. The Non-GAAP Measures are used by management to evaluate financial performance of, and determine resource allocation for, each of our operating segments. However, the Non-GAAP Measures are not measures of financial performance under U.S. GAAP. Items excluded from the Non-GAAP Measures are significant components in understanding and assessing financial performance. The Non-GAAP Measures should not be considered in isolation, or as an alternative to, or substitute for, net income, net income margin, income from operations, cash flows generated by operations, investing or financing activities, or other financial statement data presented in the consolidated financial statements as indicators of financial performance or liquidity. Because the Non-GAAP Measures are not measurements determined in accordance with U.S. GAAP and are thus susceptible to varying definitions, the Non-GAAP Measures as presented may not be comparable to other similarly titled measures of other companies. We define Adjusted EBITDA as earnings excluding interest, income taxes, depreciation and amortization, gain (loss) on early retirement of debt, stock compensation expense, separation transaction costs, and Nova Medical Centers (“Nova”) and Onsite Innovations, LLC (“Pivot Onsite Innovations”) acquisition costs. We define Adjusted EBITDA margin as Adjusted EBITDA divided by revenue. We define Return on Invested Capital as net operating profit after tax divided by average invested capital. We define Free Cash Flow as cash flow from operations less cash flow from investing activity (excluding business combinations, net of cash acquired). We define FCF Conversion as Free Cash Flow divided by net income. We will refer to the Non-GAAP Measures throughout these materials. Disclaimer 2

©2026 Concentra Inc. All rights reserved. Concentra At-a-Glance Concentra is the largest provider of occupational health services in the United States by number of locations1, with a mission of improving the health of America’s workforce, one patient at a time KEY STATISTICS ~13k Total colleagues & affiliated clinicians1,3 ~200k Employer customers2 47 States with service offerings1 ~54,000 Avg. # of patients cared for each business day2 ROBUST FINANCIALS $2.2bn TTM Revenue2 $450mm TTM Adj. EBITDA2,4 411 Onsite health clinics1 632 Occupational health centers1 <1% Revenue from government payor reimbursement2 <3% Revenue from largest employer customer2 (1) As of March 31, 2026; (2) As of TTM March 31, 2026; (3) The term "colleagues and affiliated clinicians" includes both our directly employed colleagues who provide administrative and management support to the affiliated professional medical group entities and the physicians and clinicians that are employed by the affiliated professional medical groups; (4) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income; (5) Return on invested capital ("ROIC") is a non-GAAP measure, see appendix for a reconciliation to the most comparable GAAP measure; (6) Free Cash Flow and FCF conversion are non-GAAP measures, see appendix for a reconciliation to the most comparable GAAP measures 20% TTM Adj. EBITDA margin2,4 14% Return on invested capital2,5 115% TTM FCF conversion (FCF / net income) 2,6 $212mm TTM Free Cash Flow (FCF) 2,6 3

©2026 Concentra Inc. All rights reserved. We Continue to Deliver on Goals & Key Initiatives 4 Completed acquisition of 3 locations in Southern California in Q1, and continue to advance pipeline of bolt-on M&A of small occupational health center practices (1-5 locations) Development Opened 1 de novo in Q1 (Atlanta), targeting 8-10 total de novos in 2026 Raising FY 2026 guidance for Revenue ($2.275bn-$2.375bn), Adjusted EBITDA1 ($460mm-$480mm), and Free Cash Flow3 ($215mm-$235mm) Guidance Operational & Financial Strong Q1 performance with +13.7% Revenue growth (+6.3% excluding Nova and Pivot) and +17.6% Adjusted EBITDA1 growth YoY (margin expansion of 69 basis points) Continued robust volume growth excluding Nova, most notably Workers’ Compensation growing +6.2% YoY in Q1 Steady growth in Revenue per Visit, up +3.1% YoY in Q1 Capital Allocation Continued focus on de-levering for remainder of 2026, with net leverage ratio2 steady at 3.4x in Q1 (seasonally lowest cash flow quarter of the year). On track for <3.0x guidance by year-end. $0.0625 quarterly dividend maintained, continuing to return value to shareholders 661K shares repurchased in Q1 at a weighted average share price of $22.68 (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to net income; (2) Net Leverage ratio = Net Debt / Adjusted EBITDA, per credit agreement (non-GAAP measure, see appendix for a reconciliation of reported Adjusted EBITDA to net income); (3) Free Cash Flow is a non-GAAP measure, see appendix for a reconciliation to the most comparable GAAP measure

©2026 Concentra Inc. All rights reserved. 5 Q1 2026 Performance Q1 2026 Q1 2025 YoY (∆) Commentary Facility Count (end of period) Occupational Health Centers 632 627 +5 Onsite Health Clinics 411 160 +251 Largely due to Pivot Onsite Innovations acquisition in Q2 2025 (240+) KPIs Visits per Day (“VPD”) 54.3k 50.9k 6.7% +2.9% Workers’ Compensation VPD 25.1k 22.9k 9.6% +6.2% VPD growth excluding impact of Nova acquisition Employer Services VPD 28.2k 26.9k 4.8% +0.7% Revenue per Visit (“RPV”) $151 $147 3.1% Workers’ Compensation RPV $213 $209 2.0% Employer Services RPV $97 $94 2.7% Financials ($ in millions) +6.3% Revenue growth excluding impact of Nova and Pivot Onsite Innovations Total Revenue $569.6 $500.8 13.7% Adjusted EBITDA1 $120.7 $102.7 17.6% Adjusted EBITDA margin1 21.2% 20.5% 69bps Net Income $52.3 $40.6 28.7% Net Income margin 9.2% 8.1% 107bps Capital Expenditures2 $11.1 $15.7 (29.5)% (1) Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures, see appendix for a reconciliation to the most comparable GAAP measures; (2) Excluding purchase consideration for acquisitions

©2026 Concentra Inc. All rights reserved. Balance Sheet & Capital Allocation Strategy 6 Leverage Prudent management of leverage levels, targeting <3.0x net leverage ratio by end of 2026 M&A and De Novos Strong pipeline of bolt-on acquisitions and de novos + disciplined approach to enhancing footprint for short- and long- term value creation Capital Expenditures Continued strategic investment in technology, facilities, and infrastructure Dividend Quarterly cash dividend of $0.0625 per share Share Repurchase Program 661K shares repurchased in Q1 2026 Net Leverage Ratio Liquidity $62 $434 $496 3/31/26 Cash Revolver Capacity2 ($ in millions) (1) Net Leverage ratio = Net Debt / Adjusted EBITDA, per credit agreement (non-GAAP measure, see appendix for a reconciliation of reported Adjusted EBITDA to net income); (2) $450 million revolving facility undrawn as of 3/31/26; however, Concentra has $434 million of availability under its revolving credit facility after giving effect to $16 million of outstanding letters of credit Capital Allocation Strategy (Net leverage ratio as multiple of Adj. EBITDA1, calculation per credit agreement) Continued focus on de-levering for 2026, with strong cash flow also supporting capital deployment to other attractive strategies ~3.9x 3.5x 3.9x 3.4x <3.0x July '24 (IPO) 12/31/24 3/31/25 3/31/26 12/31/26E Guidance Nova acquisition

©2026 Concentra Inc. All rights reserved. 2026 Full-Year Guidance 7(1) Adjusted EBITDA and Free Cash Flow are non-GAAP measures, see appendix for a reconciliation to the most comparable GAAP measure; (2) Net Leverage Ratio = Net Debt / Adjusted EBITDA, per credit agreement (non-GAAP measure, see appendix for a reconciliation of reported Adjusted EBITDA to net income); (3) Excluding acquisitions FY 2025 FY 2026 Guidance Commentary Total Revenue $2,163.4mm $2,275mm – $2,375mm Raising previous guidance ($2,250mm – $2,350mm) Adjusted EBITDA1 $431.9mm $460mm – $480mm Raising previous guidance ($450mm – $470mm) Net Leverage Ratio2 3.4x <3.0x Remain on track for target Free Cash Flow1 $197.8mm $215mm – $235mm Raising previous guidance ($200mm – $225mm) Capital Expenditures3 $82.3mm $70mm – $80mm Remain on track for target

©2026 Concentra Inc. All rights reserved. Reconciliation of Net Income to Adjusted EBITDA 10 Three Months Ended Mar. 31, TTM Mar. 31, ($ in thousands) 2026 2025 2026 Revenue $569,555 $500,752 $2,232,220 Net Income $52,292 $40,642 $184,499 Income Tax Expense 17,315 13,254 55,039 Interest Expense (Income) 26,003 25,548 109,745 Loss on Early Retirement of Debt − 875 − Stock Compensation Expense 4,135 2,269 12,356 Depreciation and Amortization 19,648 16,619 78,846 Separation Transaction Costs¹ 1,076 315 4,854 Nova and Pivot Onsite Innovations Acquisition Costs 219 3,137 4,553 Adjusted EBITDA $120,688 $102,659 $449,892 Net Income Margin 9.2% 8.1% 8.3% Adjusted EBITDA Margin 21.2% 20.5% 20.2% Note: May not foot due to rounding. (1) Separation transaction costs represent non-recurring incremental consulting, legal, audit-related fees, system implementation, and software disposal costs incurred in connection with the Company’s separation into a new, publicly traded company and are included within general and administrative expenses on the consolidated statements of operations.

©2026 Concentra Inc. All rights reserved. Reconciliation of 2026 Adjusted EBITDA Guidance 11 Range ($ in millions) Low High Net Income Attributable to the Company $184 $199 Net Income Attributable to Non-Controlling Interests 7 7 Net Income $191 $206 Income Tax Expense 63 68 Interest Expense 104 104 Income from Operations $358 $378 Stock Compensation Expense 21 21 Depreciation and Amortization 80 80 Separation Transaction Costs 1 1 Adjusted EBITDA $460 $480 Note: May not foot due to rounding

©2026 Concentra Inc. All rights reserved. Reconciliation to Free Cash Flow 12Note: May not foot due to rounding TTM Mar. 31, 2026 Guidance ($ in millions) 2026 Low High Net Cash Provided by Operating Activities $289 $295 $305 Net Cash Used in Investing Activities $(135) $(84) $(74) Business Combinations, Net of Cash Acquired $58 $4 $4 Free Cash Flow $212 $215 $235 Net Income $184 Free Cash Flow Conversion 115%

©2026 Concentra Inc. All rights reserved. Reconciliation to Return on Invested Capital (ROIC) 13Note: May not foot due to rounding; (1) Assumes the weighted average effective tax rate between 2023 and Q1 2026 (24.2%); (2) ROIC calculated as (i) Net Operating Profit After Tax (“NOPAT”) divided by (ii) Average Invested Capital ($ in millions) TTM Mar. 31, 2026 Operating Income $349 (x) 1-Effective Tax Rate1 76% (i) NOPAT $265 Starting Debt $1,634 Ending Debt $1,576 (a) Average Debt $1,605 Starting Equity (BV) $312 Ending Equity (BV) $432 (b) Average Equity (BV) $372 Starting Redeemable NCI (BV) $19 Ending Redeemable NCI (BV) $22 (c) Average Redeemable NCI (BV) $20 Starting Cash $52 Ending Cash $62 (d) Average Cash $57 (ii) Average Invested Capital (a)+(b)+(c)-(d) $1,941 ROIC2 13.6%

GRAPHIC

Filename: concentrainvestorpresent001.jpg · Sequence: 7

Binary file (84238 bytes)

Download concentrainvestorpresent001.jpg

GRAPHIC

Filename: concentrainvestorpresent002.jpg · Sequence: 8

Binary file (206984 bytes)

Download concentrainvestorpresent002.jpg

GRAPHIC

Filename: concentrainvestorpresent003.jpg · Sequence: 9

Binary file (148417 bytes)

Download concentrainvestorpresent003.jpg

GRAPHIC

Filename: concentrainvestorpresent004.jpg · Sequence: 10

Binary file (168656 bytes)

Download concentrainvestorpresent004.jpg

GRAPHIC

Filename: concentrainvestorpresent005.jpg · Sequence: 11

Binary file (105645 bytes)

Download concentrainvestorpresent005.jpg

GRAPHIC

Filename: concentrainvestorpresent006.jpg · Sequence: 12

Binary file (122634 bytes)

Download concentrainvestorpresent006.jpg

GRAPHIC

Filename: concentrainvestorpresent007.jpg · Sequence: 13

Binary file (86983 bytes)

Download concentrainvestorpresent007.jpg

GRAPHIC

Filename: concentrainvestorpresent008.jpg · Sequence: 14

Binary file (200107 bytes)

Download concentrainvestorpresent008.jpg

GRAPHIC

Filename: concentrainvestorpresent009.jpg · Sequence: 15

Binary file (40778 bytes)

Download concentrainvestorpresent009.jpg

GRAPHIC

Filename: concentrainvestorpresent010.jpg · Sequence: 16

Binary file (100672 bytes)

Download concentrainvestorpresent010.jpg

GRAPHIC

Filename: concentrainvestorpresent011.jpg · Sequence: 17

Binary file (73458 bytes)

Download concentrainvestorpresent011.jpg

GRAPHIC

Filename: concentrainvestorpresent012.jpg · Sequence: 18

Binary file (56758 bytes)

Download concentrainvestorpresent012.jpg

GRAPHIC

Filename: concentrainvestorpresent013.jpg · Sequence: 19

Binary file (72829 bytes)

Download concentrainvestorpresent013.jpg

GRAPHIC

Filename: image.jpg · Sequence: 20

Binary file (18616 bytes)

Download image.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 22

v3.26.1

Cover

May 05, 2026

Cover [Abstract]

Document Type

8-K

Document Period End Date

May 05, 2026

Registrant Name

CONCENTRA GROUP HOLDINGS PARENT, INC

Entity File Number

001-42188

Entity Incorporation, State or Country Code

Entity Tax Identification Number

30-1006613

Entity Address, Address Line One

5080 Spectrum Drive

Entity Address, Address Line Two

Suite 1200W

Entity Address, City or Town

Addison

Entity Address, State or Province

Entity Address, Postal Zip Code

75001

City Area Code

972

Local Phone Number

364-8000

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.01 par value per share

Trading Symbol

CON

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

Amendment Flag

false

Central Index Key

0002014596

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration